|Systematic (IUPAC) name|
|Bioavailability||~70% to 90%|
|Half-life||10 hrs (normal renal function)|
|Mol. mass||102.092 g/mol|
| (what is this?)
Cycloserine (4-amino-3-isoxazolidinone) is a drug sold under the brand name Seromycin. It is an antibiotic effective against Mycobacterium tuberculosis. Although the drug is active against other bacteria as well, it is not commonly used in the treatment of infections other than tuberculosis in the lungs and kidneys as well as urinary tract infections. For the treatment of tuberculosis, cycloserine is classified as a second line drug, i.e. its use is only considered if one or more first line drugs cannot be used. Hence, cycloserine is restricted for use only against multi-drug resistant and extensively drug resistant strains of Mycobacterium tuberculosis. Another reason for limited use of this drug is the neurological side effects it causes, since it is able to penetrate into the central nervous system (CNS) and cause headaches, drowsiness, depression, dizziness, vertigo, confusion, paresthesias, dysarthria, hyper-irritability, psychosis, convulsions, and shaking (tremors). Overdose of cycloserine may result in paresis, seizures, and coma while alcohol consumption may increase the risk of seizures. Co-administration of pyridoxine can reduce the incidence of some of these CNS side effects (e.g. convulsions) caused by cycloserine.
Since the discovery that cycloserine is able to penetrate into the CNS, numerous studies have been conducted to assess the efficacy of cycloserine for psychiatric disorders. Cycloserine has been found to be effective in the treatment of some neurological disorders, due to its effect as a selective partial agonist of the N-methyl-D-aspartate (NMDA) glutamatergic receptors found in the basolateral nucleus of the amygdala. Specifically, cycloserine affects the glycine-binding sites which are important for opening these NMDA channels.
Cycloserine is stable under basic conditions, with the greatest stability at pH = 11.5. Under mildly acidic conditions, Cycloserine breaks down into Hydroxylamine and D-Serine, whereas under prolonged hydrolysis, it breaks down into Hydroxylamine and DL-Serine.  Cycloserine exists in both the dextrorotatory and levorotatory forms, with each one having different biological properties. For instance, D-cycloserine (DCS) is a partial agonist at both the glycine receptor and the NMDA receptor, and leads to cognition-enhancing properties for primate models of Parkinson's disease. It is also being tested as an adjuvant to exposure therapy for anxiety disorders (e.g. phobias), depression, obsessive-compulsive disorder and schizophrenia. It has been experimentally used for treatment of Gaucher's disease. In contrast, L-Cycloserine(LCS) has been shown to act as a GABA transaminase inhibitor, which increases the levels of gamma-Aminobutyric acid (GABA) in the brain by inhibiting its breakdown.
- 1 Antibiotic uses
- 2 Psychiatric uses
- 3 References
Indications is a medical term referring to the reason for using a certain medication, test, or procedure. The drug Cycloserine is indicated for use in both tuberculosis and urinary tract infections.
Mechanism of antibiotic action
DCS works as an antibiotic by inhibiting cell-wall biosynthesis in bacteria.  As a cyclic analogue of D-alanine, Cycloserine acts against two crucial enzymes important in the cytosolic stages of peptidoglycan synthesis: alanine racemase (Alr) and D-alanine:D-alanine ligase (Ddl).  The first enzyme is a pyridoxal 5'-phosphate-dependent enzyme which converts the L-alanine to the D-alanine form. The second enzyme is involved in joining two of these D-alanine residues together by catalyzing the formation of the ATP-dependant D-alanine-D-alanine dipeptide bond between the resulting D-alanine molecules. If both of these enzymes are inhibited, then D-alanine residues can't form and previously formed D-alanine molecules can't be joined together. This effectively leads to inhibition of peptidoglycan synthesis in gram positive bacteria. 
This is the dextrorotatory form of the drug. This form of Cycloserine has been investigated in numerous studies focusing on fear extinction and addictions in the human and animal model systems.
Implications in fear conditioning, memory consolidation, and extinction
D-Cycloserine, when used in conjunction with exposure-based cognitive behavior therapy helps with fear extinction in an array of anxiety and stress inducing disorders. These disorders and phobias are a result of and get perpetuated through pathological fear memory. Pavlovian fear conditioning is a notable animal model to induce this form of conditioning in the lab and provides an avenue to examine mechanisms of learning and memory. In this conditioning model, a neutral and non-aversive stimulus such as light or tone (termed as the conditioned stimulus, CS) is paired with an aversive stimulus, such as an electrical shock to the foot (termed as the unconditioned stimulus, US). After these two stimuli are presented together a few times, the animals quickly learn to associate these stimuli together, and elicit a learned response, such as freezing or sweaty fingers (termed as the conditioned response, CR).
The process of extinction (associative learning) entails unlearning this association between the CS and US and results in a decrease in the frequency of the CR being elicited. This occurs by repeatedly presenting the non-aversive stimulus (CS) without the aversive stimulus (US). By repeating this numerous times, the animals learn to not associate the stimuli together, which can be examined by the decrease in frequency of the CR being elicited.  Similar to fear conditioning, extinction can be broken down into several categories, such as acquisition (training), consolidation, and retrieval of extinction memory.  Understanding the circuitry and mechanisms of extinction has strong implications for development of novel therapeutics to be used in conjunction with exposure-based cognitive behavioral therapy for patients suffering from anxiety and stress inducing disorders.  Another reason for development of pharmacological therapeutics is due to the fact that a decrease in exhibition of the CR may not always be permanent since episodes of renewal can also result.  Relapse of CR can also occur gradually with time, in lieu of other aversive events or with reinstatement (re-presentation) of the US.  Likewise, with exposure-based cognitive therapies, an impending limitation is the high rates of relapse.  For all of these reasons, there is considerable interest in the creation of pharmacological treatments to enhance extinction and reduce relapse rates. 
Many studies have shown that the extinction process is dependent upon N-methyl-D-aspartate (NMDA) receptors in the basolateral amygdala (BLA).  D-Cycloserine (DCS) is a partial agonist of the NMDA receptor, where it increases excitatory NMDA neurotransmission by binding to the glycine-binding sites. DCS has been shown to enhance extinction retention in rats. It enhances fear extinction during within-sessions which suggests that DCS facilitates the learning aspect of extinction. Though DCS has been shown to reduce some occurrences of relapse and reinstatement in humans and rats, it doesn’t seem to prevent renewal. Nevertheless, there is considerable interest in employing DCS as a treatment for psychiatric disorders, due to its beneficial therapeutic effects in several studies which have employed DCS for anxiety disorders, acrophobia, post-traumatic stress disorder, obsessive-compulsive disorder, and panic disorders.
Interaction with the NMDA receptor
Glutamate is a major excitatory neurotransmitter in the mammalian central nervous system. One of the ionotropic receptors that glutamate activates is the NMDA receptor. NMDA glutamatergic receptors are tetrameric, consisting of two NR1 subunits (which bind glycine) and two NR2 subunits (which bind glutamate). These receptors are important for synaptic plasticity and development processes in the brain. D-Cycloserine (DCS) acts as a partial agonist at NMDA receptors with NR2A, NR2B, NR2C, or NR2D subunits.DCS has lower efficacy than the endogenous agonists glycine or D-serine at the NR1/NR2A, NR1/NR2B and NR1/NR2D receptors.However, at the NR1/NR2C receptors, DCS has higher efficacy than endogenous glycine or D-serine.  It has been hypothesized that the efficacy of glycine agonists entails the differential communication between the NR2 subtypes and the NR1 receptors. This is due to the fact that residues of the NR1 domain may interact differently with the NR2 domain subtypes, especially during instances of intra-protein conformational changes at the dimer interface. This differential dimer interface interaction may explain why DCS has a higher relative efficacy than the endogenous agonists glycine or D-serine at NR1/NR2C receptors. Likewise, recordings performed with a continuous saturating concentration of the endogenous agonists glycine and glutamate have also shown that DCS decreases efficiency of gating by slowing forward rate constant preceding rapid pore openings. These psychotropic responses are related to D-cycloserine's action as a partial agonist of the neuronal NMDA receptor for glutamate and have been examined in implications with sensory-related fear extinction in the amygdala, and extinction of cocaine seeking in the nucleus accumbens.
Typically, exposure therapy is employed as a psychotherapy to help patients suffering from social anxiety disorder. Nevertheless, many patients still exude symptoms even after therapy. To help such patients, in 2006, a study found that when 50 mg of D-Cyloserine (DCS) was administered an hour prior to exposure-based Cognitive Behavior Therapy (CBT) sessions, it resulted in a much higher anxiety reduction as compared to the administration of a placebo with CBT. Additionally, the researchers also found that when DCS was given with exposure-based CBT for social performance situations such as public speaking, this also resulted in reduction of social anxiety.
Use for substance dependence disorder (drug addiction)
Cocaine addictions result in drug-seeking and drug-taking behaviors. These behaviors can be explained by the incentive sensitisation theory of addiction, in which constant drug use elicits drug-seeking behaviors due to associative learning processes which occur through Pavlovian conditioning.  During this time, drug cues gain 'motivational salience' due to sensitisation of the dopaminergic transmission in the nucleus accumbens/ventral striatal reward pathway. Gradually, this culminates in drug cues taking over attentional processes and results in cravings, drug-seeking, and relapse. A notable instance of this can be seen with cocaine addictions, which arise from pairing cocaine use with the external cues which results in conditioning and memory consolidation. The conditioned responses are cravings and relapse. Although cue exposure (extinction) therapy is currently being employed to help patients counter the motivation for drug-seeking and drug-taking behaviors, this therapy is not effective consistently, possibly due to its context-dependency as well as reliance on sound memory systems for extinction learning (which are possibly impaired with sustained cocaine use). Plus, there are no promising pharmaceuticals for treating drug addictions in the market currently and since cocaine addiction is a major problem in modern society, it is imperative that better therapeutics can be created to reverse this problem. As a result, there is considerable interest in using DCS, which has already been found to help with fear extinction in various animal as well as human model systems. Extinction of drug addiction is analogous to extinction of fear, in which active learning processes are involved. In particular, animal studies have shown that NMDA receptors are notably important for acquisition and consolidation of cocaine-cue associations in addition to extinction and reconsolidation.
Studies employing various animal model systems to assess the efficacy of DCS in treatment of cocaine addictions have yielded mixed results. For instance, in a study conducted in 2009, it was found that DCS administration two hours prior to each extinction session acutely increased cravings and susceptibility to cocaine cues in cocaine-dependant persons by stimulation of glutamatergic systems. However, in 2010, another study found that taking DCS prior to the extinction training lead to reacquisition of cocaine self-administration in rats and monkeys through augmentation of consolidation of extinction learning. This study also found that DCS was effective only when used administered in conjunction with explicit extinction therapy.  More studies will need to be conducted to reconcile and substantiate these findings.
A similar type of discrepancy is also seen in studies examining the efficacy of DCS on facilitating extinction in participants with nicotine addictions in conjunction with cue exposure therapy.  Researchers conducting a study in 2009 hypothesized that when nicotine-dependent persons receive DCS in conjunction with cue exposure therapy, they would exhibit a reduced skin conductance response in comparison to the participants receiving a placebo with cue exposure therapy. Their data suggested that when DCS was administered with cue exposure therapy 1 hour prior to each of the two 4.5 h experimental sessions, the participants indeed had a lower skin conductance response. Participants receiving the DCS also expressed a reduced urge to smoke in that study, although the evidence didn't indicate a change in their smoking behavior. However, another study, conducted in 2011 found that administration of DCS reduced nicotine self-administration in rats with lower baselines levels of response but was actually detrimental for rats with higher baseline levels. They found that chronic administration of DCS in 40 mg/kg was effective in creating these responses, implying that NMDA receptors may potentially be implicated in individuals who are trying to quit smoking. However, more studies will need to be conducted to substantiate these findings.
This is the levorotary version of the drug. L-cycloserine has been shown to irreversibly inhibit GABA pyridoxal 5′-phosphate (PLP)-dependent aminitransferase in E.Coli, as well in the brains of various animals, such as pigs, cats, and monkeys in a time-dependent manner. This results in increased levels of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in vivo, since its breakdown is halted by the inhibition of GABA transaminase.It has been suggested that small doses of LCS reduce hyperexcitability in the brain in acutely-treated and subchronically-treated animals through GABAnergic inhibition. Furthermore, a study has reported that peak effect of this inhibition can be seen 3-4 hr after a single intraperitoneal injection. LCS has also been implicated in moderately increasing alanine levels and slightly decreasing aspartate, glutamate, and glycine levels in the brain. Small doses of LCS has been shown to reduce levels of cGMP in rat cerebellums whereas small doses administered to cats attentuated the hypothalamically-elicited rage reaction. Larger doses of LCS impaired performance of mice in various tests like rotarod, chimney and horizontal wire tests. In rats, the larger doses resulted in reduction of spontaneous locomotor activity.
- "WebMD: Drugs & Medications - cycloserine oral".
- Nitsche, Michael; Jaussi, W., Liebetanz, D., Lang, N., Tergau, F., & Paulus, W. (2004). "Consolidation of human motor cortical neuroplasticity by D-cycloserine". Neuropsychopharmacology 29 (8): 1573-1578. PMID 15199378.
- Medscape (2010). "DHEA Oral". Drug Reference. WebMD LLC. Retrieved 18 February 2010.
- "CYCLOSERINE: Human Health Effects". National Institutes of Health.
- Hoffman, Stefan (2006). "Augmentation of Exposure Therapy With D-Cycloserine for Social Anxiety Disorder". Archives Of General Psychiatry 63 (3): 298-304. PMID 16520435.
- Kaushal, Gagan; Ronaldo Ramirez, Demelash Alambo, Wacharah Taupradist, Krunal Choksi, Cristian Sirbu (October 2011). "Initial characterization of D-cycloserine for future formulation development for anxiety disorders". Drug Discoveries & Therapeutics 5 (5): 253-260. PMID 22466372.
- Silverman, Richard (1998). "An Aromatization Mechanism of Inactivation of γ-Aminobutyric Acid Aminotransferase for the Antibiotic l-Cycloserine". Journal of the American Chemical Society 120 (10): 2256-2267.
- Ressler, K. J.; Rothbaum, B. O.; Tannenbaum, L.; Anderson, P.; Graap, K.; Zimand, E.; Hodges, L.; Davis, M. (2004). "Cognitive Enhancers as Adjuncts to Psychotherapy: Use of D-Cycloserine in Phobic Individuals to Facilitate Extinction of Fear". Archives of General Psychiatry 61 (11): 1136. doi:10.1001/archpsyc.61.11.1136. PMID 15520361.
- Davis, M.; Myers, K. M.; Ressler, K. J.; Rothbaum, B. O. (2005). "Facilitation of Extinction of Conditioned Fear by D-Cycloserine. Implications for Psychotherapy". Current Directions in Psychological Science 14 (4): 214. doi:10.1111/j.0963-7214.2005.00367.x.
- Davis, M.; Ressler, K.; Rothbaum, B. O.; Richardson, R. (2006). "Effects of D-Cycloserine on Extinction: Translation from Preclinical to Clinical Work". Biological Psychiatry 60 (4): 369–375. doi:10.1016/j.biopsych.2006.03.084. PMID 16919524.
- Heresco-Levy, U.; Gelfin, G.; Bloch, B.; Levin, R.; Edelman, S.; Javitt, D. C.; Kremer, I. (2012). "A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression". The International Journal of Neuropsychopharmacology 16 (3): 501–506. doi:10.1017/S1461145712000910. PMID 23174090.
- Chan, H. N.; Alonzo, A.; Martin, D. M.; Mitchell, P. B.; Sachdev, P.; Loo, C. K. (2013). "Augmenting Transcranial Direct Current Stimulation with D-Cycloserine for Depression". The Journal of ECT 29 (3): 196–200. doi:10.1097/YCT.0b013e3182801b09. PMID 23792778.
- Kushner, M. G.; Kim, S. W.; Donahue, C.; Thuras, P.; Adson, D.; Kotlyar, M.; McCabe, J.; Peterson, J.; Foa, E. B. (2007). "D-Cycloserine Augmented Exposure Therapy for Obsessive-Compulsive Disorder". Biological Psychiatry 62 (8): 835–838. doi:10.1016/j.biopsych.2006.12.020. PMID 17588545.
- Goff, D.; Cather, C.; Gottlieb, J.; Evins, A.; Walsh, J.; Raeke, L.; Otto, M.; Schoenfeld, D.; Green, M. (2008). "Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study". Schizophrenia Research 106 (2–3): 320–327. doi:10.1016/j.schres.2008.08.012. PMC 2628436. PMID 18799288.
- Gottlieb, J. D.; Cather, C.; Shanahan, M.; Creedon, T.; MacKlin, E. A.; Goff, D. C. (2011). "D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia". Schizophrenia Research 131 (1–3): 69–74. doi:10.1016/j.schres.2011.05.029. PMC 3389827. PMID 21723096.
- Evins, A. E.; Amico, E.; Posever, T. A.; Toker, R.; Goff, D. C. (2002). "D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia". Schizophrenia research 56 (1–2): 19–23. doi:10.1016/S0920-9964(01)00220-1. PMID 12084415.
- Schneider, J. S.; Tinker, J. P.; Van Velson, M.; Giardiniere, M. (2000). "Effects of the partial glycine agonist D-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys". Brain research 860 (1–2): 190–194. doi:10.1016/S0006-8993(00)02036-9. PMID 10727642.
- Polc, P.; Pieri, L.; Bonetti, E. P.; Scherschlicht, R.; Moehler, H.; Kettler, R.; Burkard, W.; Haefely, W. (1986). "L-cycloserine: Behavioural and biochemical effects after single and repeated administration to mice, rats and cats". Neuropharmacology 25 (4): 411–418. doi:10.1016/0028-3908(86)90236-4. PMID 3012401.
- Epstein, I. G.; Nair, K. G.; Boyd, L. J. (1955). "Cycloserine, a new antibiotic, in the treatment of human pulmonary tuberculosis: A preliminary report". Antibiotic medicine & clinical therapy 1 (2): 80–93. PMID 14362439.
- Fairbrother, R. W.; Garrett, G. (1960). "Treatment of urinary infections with cycloserine". British medical journal 2 (5207): 1191–1194. doi:10.1136/bmj.2.5207.1191. PMC 2096985. PMID 13697941.
- Lambert, M. P. (1972). "Mechanism of D-cycloserine action: Alanine racemase from Escherichia coli W". Journal of bacteriology 110 (3): 978–987. PMID 4555420.
- Prosser, Gareth; Luiz Pedro S. de Carvalho (February 2013). "Kinetic mechanism and inhibition of Mycobacterium tuberculosis d-alanine: D-alanine ligase by the antibiotic d-cycloserine". FEBS Journal 280 (4): 1150-1166. PMID 23286234.
- Ren, Jintao; Xiaobai Li , Xinxin Zhang, Min Li, Yan Wang, Yuchao Ma (July 2013). "The effects of intra-hippocampal microinfusion of d-cycloserine on fear extinction, and the expression of NMDA receptor subunit NR2B and neurogenesis in the hippocampus in rats". Progress In Neuro-Psychopharmacology And Biological Psychiatry 44: 257-264. PMID 23523746.
- Baker, Kathryn; Gavan P. McNally, and Rick Richardson (October 2012). "D-cycloserine does not facilitate fear extinction by reducing conditioned stimulus processing or promoting conditioned inhibition to contextual cues". Learning And Memory 19 (10): 461-469. PMID 22984284.
- Dravid, Shashank; Pieter B. Burger, Anand Prakash, Matthew T. Geballe, Roopali Yadav, Phuong Le, Kimberly Vellano, James P. Snyder, and Stephen F. Traynelis (February 2010). "Structural determinants of D-cycloserine efficacy at the NR1/ NR2C NMDA receptors". The Journal Of Neuroscience: The Official Journal Of The Society For Neuroscience 30 (7): 2741-2754. PMID 20164358.
- Walker, D. L.; Ressler, K. J.; Lu, K. T.; Davis, M. (2002). "Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats". The Journal of neuroscience : the official journal of the Society for Neuroscience 22 (6): 2343–2351. PMID 11896173.
- Torregrossa, M. M.; Sanchez, H.; Taylor, J. R. (2010). "D-Cycloserine Reduces the Context Specificity of Pavlovian Extinction of Cocaine Cues through Actions in the Nucleus Accumbens". Journal of Neuroscience 30 (31): 10526–10533. doi:10.1523/JNEUROSCI.2523-10.2010. PMC 2918879. PMID 20685995.
- Dhonnchadha, Brid; Jonathan J Szalay, Cindy Achat-Mendes, Donna M Platt, Michael W Otto, Roger D Spealman and Kathleen M Kantak (January 2010). "D-cycloserine Deters Reacquisition of Cocaine Self-Administration by Augmenting Extinction Learning". Neuropsychopharmacology: Official Publication Of The American College Of Neuropsychopharmacology 35 (2): 357-367. PMC PMC2928163.
- Kamboj, Sanjeev; Alyssa Joye & Ravi K. Das & Andrew J. W. Gibson & Celia J. A. Morgan & H. Valerie Curran (May 2012). "Cue exposure and response prevention with heavy smokers: A laboratory-based randomised placebo-controlled trial examining the effects of D-cycloserine on cue reactivity and attentional bias". Psychopharmacology 221 (2): 273-284. PMID 22101394.
- Price, Kimber; Aimee L. McRae-Clark, Michael E. Saladin, Megan M. Moran-Santa Maria, Stacia M. DeSantis, Sudie E. Back, and Kathleen T. Brady (November 2009). "D-Cycloserine and Cocaine Cue Reactivity: Preliminary Findings". American Journal Of Drug & Alcohol Abuse 35 (6): 434-438. PMID 20014913.
- Santa-Anna, Elizabeth; Bruce J. Rounsavillea, Tami L. Frankforter, Charla Nich, Theresa Babuscio, James Polinga, Kishorchandra Gonsaia, Kevin P. Hill, Kathleen M. Carroll (October 2009). "d-Cycloserine attenuates reactivity to smoking cues in nicotine dependent smokers: A pilot investigation". Drug And Alcohol Dependence 104 (3): 220-227. PMID 19592176.
- Levin, Edward; Susan Slade, Corinne Wells, Ann Petro, Jed E. Rose (2011). "D-cycloserine selectively decreases nicotine self-administration in rats with low baseline levels of response". Pharmacology Biochemistry And Behavior 98 (2): 210-214. PMID 21192967.
- Polc, P.; L. Pieri, E.P. Bonetti, R. Scherschlicht, H. Moehler, R. Kettler, W. Burkard, and W. Haefely (April 1986). "Behavioural and biochemical effects after single and repeated administration to mice, rats and cats". Neuropharmacology 25 (4). PMID 3012401.